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Poly(DL-lactide-co-ε-caprolactone)/poly(acrylic acid) implantable composite reservoirs for 
cationic drugs are synthesized by sequentially applying photoirradiation and liquid phase 
inversion. The chemical composition and microstructure of reservoirs are characterized with 
FTIR-ATR and SEM, respectively. Drug loading and release properties are investigated using 
methylene blue as the drug model. Biocompatibility of reservoirs is examined through a series 
of in vitro tests and an in vivo experiment of subcutaneous implantation in Dark Agouti rats. 
Reservoirs show good ion-exchange capacity, high water content and fast reversible swelling 
with retained geometry. Results of drug loading and release reveal excellent loading 
efficiency and diffusion-controlled release during two weeks. Biocompatibility tests in vitro 
demonstrate the lack of implant proinflammatory potential and hindered adhesion of L929 
                                                 
a
 Supporting Information is available online from the Wiley Online Library or from the author. 
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cells on the implant surface. Implants exhibit low acute toxicity and elicit a normal acute 
foreign body reaction that reaches the early stages of fibrous capsule formation after seven 
days.  
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1. Introduction  
Implantable systems are a promising approach for the delivery of drugs that cannot be 
efficiently delivered via the oral route or when site-specific dosing is beneficial for the 
patient. Prominent material classes used in drug delivery implants are biodegradable polymers 
and hydrogels.  
Biodegradable polymers commonly found in implantable drug delivery systems are 
poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), poly(caprolactone) (PCL), or 
their block copolymers.
[1]
 These biodegradable polymers offer the advantage of avoiding 
surgical procedure for implant removal because they are safely metabolized and absorbed or 
released by excretion from the body.
[2,3]
  
Hydrogels are cross-linked polymeric networks with high water content and physical 
properties resembling soft tissues of the body. Adjustable physical properties, controllable 
degradation, good biocompatibility, and capability for facile encapsulation of hydrophilic 
drugs are major advantages favoring the use of hydrogels in controlled drug release 
systems.
[4]
 
Hydrogels containing functional groups with fixed charges act as polyelectrolytes in aqueous 
solutions. Such behavior can be exploited to control the release of charged drugs via 
nonspecific electrostatic interaction.
[5,6]
 Release of these charged drugs occurs by ion 
exchange with mobile counter ions of the surrounding medium. Analogous to the 
pharmaceutical grade ion-exchange resins, charged hydrogels exhibit high drug loading 
capacity
[7]
 and enhance drug stability
[8]
. Poly(acrylic acid) (PAA) hydrogel is an interesting 
material for the controlled delivery of cationic drugs because of abundant carboxyl groups 
enabling cation exchange.
[9]
 Carboxyl groups on the surface of a biomaterial may have 
additional functions in vivo, such as the reduction of the inflammatory response and the 
suppression of fibrotic capsule formation which would facilitate drug release.
[10] 
    
 - 4 - 
However, pure PAA hydrogel has unfavorable mechanical properties. It exhibits a very high 
swelling degree under physiological conditions
[11]
 and may suffer from spatial gel 
inhomogeneity
[12]
 which is typical for hydrogels. PAA hydrogel can be reinforced with a 
more stable polymer matrix by forming a composite material to alleviate mechanical 
instability. 
Composite materials comprising a biodegradable polymer and a functional PAA hydrogel 
could be useful as implantable reservoirs for controlled delivery of cationic drugs. 
Copolymerization of PAA and chitosan was used in the past to obtain biocompatible magnetic 
microspheres
[13]
 and composite membranes with antibacterial properties
[14]
. Stankevich et al. 
fabricated composites of PAA and PLA for biomedical applications by immobilizing PAA as 
a chemically reactive cross-linker on the surface of PLA.
[15]
 
In our previous work, we synthesized the poly(ether sulfone)/PAA composite hydrogel 
membrane reservoirs for transdermal delivery of cationic drug formulations by sequential 
application of photoirradiation and immersion precipitation.
[16]
 As we show here, this 
innovative synthesis method can be modified and adapted for the fabrication of implantable 
drug reservoirs. 
In this study, we present the synthesis and characterization of poly(DL-lactide-co-ε-
caprolactone)/PAA implantable drug reservoir for controlled release of cationic drugs. The 
microstructure of the implants is imaged using Scanning electron microscopy (SEM), and 
their chemical composition is examined with Fourier transform infrared spectroscopy-
Attenuated total reflection (FTIR-ATR). We investigate the loading capacity and in vitro 
release kinetics for methylene blue (MB) as a cationic model drug. Biocompatibility of the 
unloaded implant is tested in vitro using L929 mouse fibroblast cell line and splenocytes 
isolated from male Dark Agouti rat. Finally, we perform a pilot experiment for the 
preliminary assessment of acute in vivo response to the subcutaneously implanted unloaded 
drug reservoirs. Subcutaneous tissue is chosen as a representative implantation site which is 
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preferred for implantable drug reservoirs because it exhibits adequate hemoperfusion, low 
innervation, reduced risk of local inflammation, and high fat content beneficial for retarding 
drug absorption.
[17]
 
 
2. Experimental Section  
2.1. Materials 
25:75 poly(DL-lactide-co-ε-caprolactone) (DL-PLCL) (Mw = 96700, PDI = 1.61) was 
obtained from DURECT Corporation. N-methyl-2-pyrrolidone (NMP) (99%), acrylic acid 
(AA) (99%), and trimethylolpropane ethoxylate triacrylate (TMPTA) (average Mn ~ 912) 
were supplied by Sigma-Aldrich. Photoinitiator (PI), bis(2,4,6-trimethylbenzoyl)-
phenylphosphineoxide (Irgacure 819), was kindly provided by Ciba SC. MB powder (Reag. 
Ph Eur) was obtained from E. Merck. 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) (≥97.5%), crystal violet (≥90%), N-(1-naphthyl) ethylenediamine 
dihydrochloride (≥98%), and sulphanilamide (≥99%) were supplied by Sigma. Sodium 
hydroxide (NaOH) (p.a., >98%), phosphoric acid (ortho-Phosphoric acid, p.a., >85%), sodium 
chloride (NaCl) (p.a., >99.5%), potassium chloride (KCl) (p.a., >99%), di-Sodium hydrogen 
phosphate (Na2HPO4) (p.a., >98%), and potassium dihydrogen phosphate (KH2PO4) (p.a., 
>99%) were purchased from Centrohem, Stara Pazova, Serbia. Hydrochloric acid (HCl) 
(37%) and n-heptane (≥99%) were supplied by VWR Chemicals. Ethanol (p.a.) and 96 vol% 
ethanol were obtained from Zorka Pharma, Šabac, Serbia. 
Phosphate-buffered saline (PBS) for the experiments related to implant preparation, implant 
swelling degree, implant swelling kinetics, MB absorption, and MB release in vitro was 
prepared by titration of the aqueous solution of KH2PO4 with the aqueous solution of NaOH 
until the pH = 7.4 and ionic strength I = 0.154 M were reached. PBS used in biocompatibility 
tests was prepared by dissolving 8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4, and 0.24 g of 
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KH2PO4 in 800 mL of distilled water. pH of the solution was adjusted to 7.4 if necessary and 
distilled water was finally added to obtain a total volume of 1 L. 
Culture medium RPMI-1640 (Biowest, Nuaille, France) supplemented with 2 mM glutamine, 
20 mg mL
-1
 gentamycin (Galenika a. d., Zemun, Serbia), and 5 vol% heat-inactivated fetal 
calf serum (FCS) (Biowest, Nuaille, France) was used for in vitro and in vivo tests. For use in 
experiments, Concanavalin A (ConA) from Canavalia ensiformis (Jack bean), Type IV-S 
(Sigma Chemical Co., St. Louis, MO, USA) was dissolved in RPMI-1640 medium. MTT and 
crystal violet were dissolved in PBS. Griess reagent was prepared by mixing equal volumes of 
0.1% N-(1-naphthyl) ethylenediamine dihydrochloride dissolved in water and 1% 
sulphanilamide in 5% phosphoric acid solution in water.   
All chemicals were used as received without further purification. Distilled water was used to 
prepare all aqueous solutions in our experiments. All solutions for cell culture experiments 
were prepared under sterile conditions and were sterile filtered (Minisart, pore size 0.20 µm, 
Sartorius Stedim Biotech, Goettingen, Germany) before use.  
Teflon rings (PTFE Flat Washer) had the nominal thickness of 0.787 mm and a hole size of 
11.11 mm. Fluorinated ethylene propylene non-stick film of 25 μm thickness was supplied by 
Scientific Commodities, Inc.. Flasks and plates for cell cultivation were purchased from Nunc 
(Hannover, Germany). 
2.2.  Implant preparation 
For the preparation of composite implants, the traditional liquid phase inversion process for 
making membranes
[18]
 was modified by incorporating AA and a trifunctional cross-linker 
(TMPTA) in the polymer solution and copolymerizing them before the immersion in the PBS. 
A 30 wt% solution of DL-PLCL in NMP was prepared by mixing overnight. Solutions of AA, 
TMPTA, and PI in NMP were freshly prepared by mixing the components in amber vials 
cooled with ice and protected from ambient light. The solution for making implants was 
prepared by mixing a given quantity of DL-PLCL solution with a solution of 
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photopolymerizable components just prior to the experiment. All prepared solutions were 
transparent confirming complete miscibility of the components. DL-PLCL concentration in 
the solution is expressed in wt%. AA concentration is expressed in mmol g
-1
 of the final dry 
implant at a theoretical 100% reactant conversion. The concentration of the cross-linking 
agent is expressed as a mol% based on the AA concentration. 
The prepared solution was dispensed into a non-stick mold constructed by sealing the Teflon 
ring at the top and bottom with layers of transparent non-stick film to prevent leakage and 
oxygen penetration. The solution was subsequently exposed to UV irradiation of the 
wavelength λ = 365 nm through a glass plate on top of the mold for 3 min. The exposure dose 
measured by the YK-35UV light meter was 3.6 J cm
-2
. Polymerization and cross-linking of 
AA were initiated by UV exposure to create a gel in the starting solution. After UV curing, a 
non-stick plunger was used to drop the gel into the PBS bath to form a disk-shaped implant. 
Implants were left in the PBS bath overnight to complete phase separation and solidification, 
and to extract residual unreacted components. Implants were then immersed in the fresh PBS 
solution and kept refrigerated to prevent microbial contamination and retard the degradation 
process. Implants intended for in vitro and in vivo biocompatibility tests were prepared in a 
laminar flow hood under sterile conditions. These implants were left in the sterile filtered 
buffer for 24 h at 4 °C to extract the remaining solvent, unreacted monomers, and PI. Implants 
were then washed in 96 vol% ethanol for 1 h and left to dry in the sterile atmosphere for 45 
min followed by washing in medium (for spleen cells) or PBS (for L929 cell line or in vivo 
experiments) for 2 h at 4 °C. 
2.3.  Implant characterization 
2.3.1. FTIR-ATR and SEM 
FTIR-ATR analysis was conducted with Thermo Scientific Nicolet iS10 FTIR Spectrometer 
instrument equipped with Smart iTX ATR Diamond accessory. The spectra were recorded in 
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the range of 400-4000 cm
-1
 with the resolution of 0.5 cm
-1
 and then normalized to the highest 
peak intensity.  
Microstructural properties of implant surfaces were examined with the field emission SEM 
(TESCAN MIRA 3 XMU). Before the recording, dry implant samples were cooled in liquid 
nitrogen, fractured and sputtered with carbon. 
Dry implant samples were prepared for FTIR-ATR and SEM characterization using the 
solvent exchange drying protocol. Wet implant samples were dipped for 1 h in ethanol, then 1 
h in heptane, and finally air-dried for at least 24 h at ambient temperature. 
2.3.2. Mass swelling degree and water content 
Before the experiment, the implant was equilibrated in PBS for 24 h. In the beginning, the 
mass of a wet implant specimen was measured. The specimen was subsequently dried in an 
oven at 100 °C for 2 h, and finally, the mass of the dry implant was determined. The 
experiment was performed in triplicate. 
Mass swelling degree (MSD) was calculated based on the wet implant mass at time t, mt, and 
the dry implant mass, m0, measured at the end of the experiment, according to the following 
formula 
MSD = 100 ∙ (𝑚𝑡 − 𝑚0)/𝑚0 (%)        (1) 
Water content (WC) of the implant was calculated using the following equation 
WC = 100 ∙ MSD/(100 + MSD) (%)       (2) 
2.3.3. Swelling kinetics 
Swelling kinetics in PBS were monitored by measuring the MSD of the implant at predefined 
time intervals until the equilibrium MSD was achieved. Mass of the wet implant equilibrated 
in PBS was measured, and then the implant was air-dried at ambient temperature for 72 h. 
Dry mass of the implant was measured before the experiment. At the beginning of the 
experiment, the dry implant was immersed into the excess amount of PBS in a Petri dish.  
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After 2 min, the implant was taken out and carefully blotted using filter paper. Its wet mass 
was recorded, and the implant was immediately returned to the PBS solution. This procedure 
was repeated every 2 min until the equilibrium MSD was reached. Recording of the implant 
swelling kinetics was performed in triplicate. 
2.3.4. Determination of carboxyl group concentration 
Determination of carboxyl group concentration was carried out using the potentiometric acid-
base titration method. One wet implant (about 40 mg of dry mass) was broken into pieces and 
immersed in 100 mL of 0.1 M HCl solution. The solution was stirred for 1 h to protonate all 
carboxyl groups in the sample and then the sample was thoroughly rinsed with distilled water. 
The protonated sample was subsequently submerged in 40 mL of 0.01 M NaOH solution, and 
the mixture was stirred again for 1 h in a capped beaker. The sample was then separated from 
the residual solution, rinsed with distilled water, dried for 2 h at 100 °C, and the dry mass of 
the sample was finally weighed. Two aliquots of 15 mL of residual solution were titrated with 
0.01 M HCl, and the change in pH was monitored with a pH-meter (HI 3222, Hanna 
Instruments) to determine the equivalence point. As a blank probe, 15 mL of 0.01 M NaOH 
solution was titrated with 0.01 M HCl. The experiment was performed in duplicate. 
The concentration of carboxyl groups (Ccg) was calculated according to the following 
expression  
Ccg(mmol g−1) = 0.4(1 − 𝑉2/𝑉1)/𝑊d       (3) 
where V1 is the volume of 0.01 M HCl solution consumed for the titration of the blank probe, 
V2 is the volume of 0.01 M HCl solution consumed for the titration of the residual solution 
aliquot, and Wd is the mass of the dry sample. 
2.3.5. Absorption of MB 
A wet implant previously equilibrated in PBS was carefully blotted with tissue paper, and its 
wet mass was measured. The wet implant was then immersed in 25 mL of 1000 μg g-1 MB 
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aqueous solution for 120 h. The molar amount of MB in the loading solution corresponded to 
the number of carboxyl groups measured for the implant (n(MB
+
)/n(-COOH) = 1). MB 
absorption experiment was replicated three times. 
2.3.6. The release of MB in vitro 
Implant loaded with MB was rinsed with distilled water, and its surface was carefully blotted 
with a paper tissue. The prepared implant was subsequently immersed in 50 mL of PBS. The 
solution with the implant was kept at 37.0 ± 0.1 °C in the water bath during the MB release 
experiment. Aliquots of 3 mL were taken at predefined time intervals for 28 days to follow 
the release kinetics. Immediately after each sampling, the entire solution volume was replaced 
with the same volume of fresh PBS. Release kinetics were monitored with the UV-vis 
spectrophotometer (GBC Cintra 101) at the absorption wavelength of 664 nm. MB release 
experiments were performed in triplicate. 
2.4.  Biocompatibility tests 
2.4.1. Cell culture 
L929 mouse fibroblast cell line (the European Collection of Animal Cell Cultures) was grown 
in RPMI 1640 supplemented with 10% FCS and gentamycin at 37 °C in a humidified 
atmosphere with 5% CO2. Following conventional trypsinization procedure, cells were 
seeded, with or without implants (2 × 10
4
 cells/well in a 24-well plate), and incubated during 
1, 2, 4 and 24 h. At indicated times, cells were detached from plates/implants, and the cell 
suspension was kept the next 24 h in a 96-well plate (five replicates for each condition) and 
used for viability tests.  
The spleen cells were isolated from male Dark Agouti rat (6 weeks old) as described 
previously.
[19]
 Spleen tissue was mechanically disintegrated through a cell strainer (BD 
Falcon, BD Bioscience, Bedford, USA), and cells were resuspended in RPMI-1640 culture 
medium. Cell viability determined by Trypan blue dye (dye content ~40%) (Fluka, Sigma- 
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Aldrich, USA)  exclusion was larger than 90%. The isolated spleen cells (0.5 × 10
6
 cells mL
-
1
) were seeded in 24-well microtiter plates, with or without implants, and incubated for 24 and 
48 h under standard conditions (5% CO2, 37 °C).  
2.4.2. Animal study 
Male Dark Agouti rats (12-14 weeks old), conventionally housed at the Institute for 
Biological Research “Sinisa Stankovic” (IBISS), University of Belgrade, Serbia, were used in 
the pilot experiment. Experimental procedures were carried out in compliance with the 
Directive 2010/63/EU on the protection of animals used for experimental and other scientific 
purposes and were approved by the Ethical Committee of IBISS. 
For implantation, animals were anesthetized by intraperitoneal administration of 40 mg kg
-1
 of 
body weight of thiopental sodium (Rotexmedica, Tritau, Germany). The dorsum was clipped 
of hair, two incisions were made on either side of the dorsal midline, as described by Mirkov 
et al.
[20]
, and one implant was aseptically implanted subcutaneously on each side of five rats. 
Control rats (n = 5) were sham-operated. Following the procedure, animals were housed 
individually for 1, 3 and 7 days post implantation (p.i.).  
After 1, 3 and 7 days, rats were reanesthetized, and implants were quickly taken out through 
skin incisions. Overlying skin was taken for histological analysis and short-term culture of 
skin explants, as described by Popov Aleksandrov et al..
[21]
 Blood was collected for complete 
blood tests analyses conducted using a Siemens ADVIA 120 flow cytometer (Terytown, N.Y., 
USA). 
2.4.3. Cell activity tests 
MTT: The metabolic activity of cells was assessed by MTT quantitative colorimetric assay.
[22]
 
After cultivation in the absence or presence of implants, 0.5 mg mL
-1
 MTT was added to 
L929 and spleen cells and incubated for 2 h at 37 °C. Formazan was dissolved by overnight 
incubation in 10% sodium dodecyl sulfate (Merck-Schuchardt, Germany) (SDS)-0.01 N HCl. 
Absorbance was measured spectrophotometrically at 540/650 nm, by an Enzyme-linked 
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immunosorbent assay (ELISA) 96-well plate reader (GDV EC, Roma, Italy). Skin cell 
viability was also determined by MTT reduction assays, as described by Popov Aleksandrov 
et al..
[21]
 The skin was cut into small pieces and placed in wells of 96-well plates.  MTT was 
added (0.5 mg mL
-1
), and the skin was incubated for 3 h. Produced formazan was dissolved 
by overnight incubation of skin explants in 2-methoxyethanol (Fluka AG, Buchs SG, 
Switzerland) and evaluated spectrophotometrically. 
Crystal violet: Cell adhesion was evaluated with a Crystal violet assay. L929 cells were 
washed in PBS and fixed with glutaraldehyde (Sigma) (2.5 vol%) at 4 °C for 20 min, then 
stained with crystal violet (1%) for 30 min. After washing with tap water, crystal violet was 
solubilized with 0.5% SDS, and the absorbance was measured spectrophotometrically at 
540/650 nm, by an ELISA 96-well plate reader. 
NO: For NO production, cells isolated from spleen (1 × 10
6
/well) were grown in complete 
RPMI-1640 medium with or without ConA (1 µg mL
-1
) in 96-well plates for 48 h, and NO 
level was measured using Griess reaction, as described elsewhere.
[23]
 NO levels were also 
measured in conditioned media of skin explants. 
ELISA: Levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in serum or media 
conditioned by skin explants for 48 h were determined with ELISAs for rat TNF-α 
(eBioscience Inc., San Diego, CA) and rat IL-6 (R&D systems, Minneapolis, MN) according 
to manufacturer’s instructions.  
2.4.  Statistical analysis 
All quantitative data were reported as a mean ± standard deviation (SD) of the sample from 
the number of experiments indicated individually for each of the used methods. Results of in 
vitro experiments with cells (all samples were set in five replicates) and in vivo experiments 
(with four animals assigned to each experimental group) were expressed as mean ± SD and 
statistical analysis was performed using STATISTICA 7.0 (StatSoft Inc., Tulsa, OK). 
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Statistical significance was defined by a Mann-Whitney U test and P-values less than 0.05 
were considered as significant.  
 
3. Results and Discussion  
3.1. FTIR-ATR characterization 
Figure 1a shows the spectra of the pure polymer base and implant dried by solvent exchange. 
Several absorption bands are prominent in the DL-PLCL spectrum: symmetrical valence 
vibrations of C-O-C in the aliphatic chain at 1093 cm
-1
, symmetric C-O-C stretching at 1161 
cm
-1
, asymmetric C-H bending in CH3 at 1453 cm
-1
, C=O stretching at 1732 cm
-1
, and the 
CH2 stretching bands at 2867 cm
-1
 and 2940 cm
-1
. Absorption bands indicating the presence 
of PAA in dry implant are the C-O stretching bands at 1404 cm
-1
 and 1560 cm
-1
, and the O-H 
stretching band at 3384 cm
-1
. The absorption bands corresponding to the pure DL-PLCL or 
PAA components are not shifted indicating a physical blending of separated phases without 
the formation of new chemical bonds. Figure 1b depicts spectra of dry and wet implants. The 
new absorption band at 1637 cm
-1
 in wet implant spectrum corresponds to the hydrogen 
bonding of carboxyl groups. The dominant absorption band with the highest intensity in this 
spectrum is the O-H stretching band at 3384 cm
-1
. Both these bands are common indicators of 
PAA hydrogel formation. 
(Figure 1) 
3.2. SEM characterization 
SEM images of the surface and cross section of the implant are shown in Figure 2. The 
heterogeneous microstructure of the implant comprises a continuous DL-PLCL polymer 
matrix filled with PAA hydrogel inclusions. The marked difference in hydrogel distribution 
can be observed between the surface and cross section. Sparsely dispersed isolated aggregates 
of irregular PAA particles with the average cluster size of about 1.1 μm can be observed at the 
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surface. Throughout the cross section, spheroidal PAA particles with a mean diameter of 
around 280 nm are uniformly and densely packed within the DL-PLCL matrix. Hydrogel 
particles appear to be attached to the polymeric support in both regions. 
(Figure 2) 
The microstructure of the composite implant results from the complex interplay of 
phenomena occurring during the fabrication process. Photoirradiation by UV light triggers 
polymerization and cross-linking of AA initiating the phase separation, as confirmed by 
solution hazy appearance. After the immersion and solidification in the PBS bath, discs turned 
white and formed hydrogel-filled composite implants. Aqueous environment imposes 
unstable thermodynamic conditions leading to the completion of phase separation between the 
hydrophilic cross-linked PAA hydrogel-rich phase and the hydrophobic DL-PLCL polymer-
rich phase. Hydrogel-rich phase is dispersed throughout the implant volume in the form of 
submicron size particles and their aggregates close to the surface, while the DL-PLCL-rich 
phase acts as the surrounding matrix. Polymer gels commonly exhibit locally nonuniform 
spatial distributions of polymer network concentration and cross-linking density.
[24]
 
Formation of small hydrogel particles or their isolated aggregates can be explained by the 
higher rate of polymerization achieved with the trifunctional cross-linker TMPTA in 
comparison with the monofunctional AA monomer. Hence, microgels are formed after the 
cross-linker depletion in the system.  The surface of the composite implant has a lower 
hydrogel content compared to the bulk. The mechanism by which this surface layer is created 
is similar to the mechanism of skin formation in membrane fabrication by immersion 
precipitation.
[25]
 Immediately after the immersion into the PBS bath, NMP is quickly depleted 
from the irradiated disc while the PBS solution slowly penetrates towards the interior. Such a 
phenomenon leads to the formation of a skin layer enriched in DL-PLCL with embedded 
sparsely dispersed aggregates of PAA-rich phase. 
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3.3. Basic properties (MSD, WC, and Ccg) and swelling kinetics 
Implant formulation comprised 16 wt% of DL-PLCL and 20 wt% of AA and cross-linker. The 
concentration of TMPTA was 10 mol%. The basic properties of the obtained implants are 
listed in Table 1.  
(Table 1)  
Implants exhibit a moderate swelling degree and good ion-exchange capacity. Measurements 
of the basic parameters have very low SDs indicating a robust method of implant preparation 
that yields high reproducibility. MSD of the composite implant is significantly lower 
compared to the values for pure PAA hydrogel in PBS solution.
[11]
 Such a result is expected 
because the DL-PLCL polymeric base limits PAA hydrogel swelling and improves the 
mechanical stability of the implants. High WC of the implant equilibrated in PBS reveals the 
predominant hydrophilic nature of the implant that commonly indicates better 
biocompatibility and reduced inflammatory response.
[26]
 Value of Ccg is comparable to a 
typical ion-exchange resin. 
Figure 3 shows that the implant retains disc geometry during the drying and swelling and that 
MSD reaches its equilibrium value after about 6 min.  
(Figure 3) 
Swelling within few minutes was previously reported only for superporous hydrogels 
(SPHs).
[27]
 SPHs are hydrophilic polymer networks able to quickly imbibe vast amounts of 
water because of a structure containing interconnected microscopic pores that allow capillary 
action.
[28]
 Our composite implant is not a porous structure, but rather contains closely packed 
microgel particles within the hydrophobic polymer matrix. 
Swelling kinetics of the implant seems to be well described by the Boltzmann (sigmoidal) 
function. Initial lag in swelling shown in Figure 3b can be explained by the skin layer with 
lower hydrogel content, which acts as a barrier to the penetration of PBS. PAA-rich microgel 
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particles in the interior swell rapidly as a result of their small size and strongly hydrophilic 
surface. After the swelling of surface hydrogel aggregates, implant surface becomes 
negatively charged and electrostatically attracts buffer cations. The high density of negative 
charges in the swollen state and dense packing of interior microgel particles further increase 
the rate of cation penetration and hydrogel formation. 
Equilibrium MSD established in PBS after one cycle of air drying at ambient temperature is 
nearly the same as the initial MSD, which indicates implant capability of reversible swelling. 
Reversible swelling and fast swelling kinetics of the composite implant can facilitate the use 
and storage of the implant in the clinical setting. Implants can be stored and transported in the 
dry state after the drug is loaded. Before the application, the composite implant can be quickly 
rehydrated and used at the point of care. 
3.4. Studies of MB absorption and release in vitro 
The composite implant exhibited excellent loading efficiency of 95.8 ± 0.4% after MB 
absorption implying that excessive amount of MB in the absorption solution was not required.  
A total of 85.1 ± 1.8% of the loaded MB amount was released in the PBS solution at the end 
of the in vitro release experiments at 37 °C, while the residual amount of about 15% remained 
bound to the implant. The ratio of the released and bound fractions of MB gives the 
approximate ratio of MB amounts bound by electrostatic and hydrophobic forces, 
respectively. Relative cumulative amount of released MB Qt/Qe is presented as a function of 
t
0.5
 in Figure 4.  
(Figure 4) 
Concentrations of released MB at time t, Qt, were normalized to the equilibrium concentration 
of released MB, Qe, reached at the end of the experiment. The release kinetics of MB exhibits 
Fickian behavior which extends even to longer times. The released amount is diffusion-
controlled and easy to predict in the initial period of around 14 days. The calculated apparent 
diffusion coefficient was Da = 3.54 × 10
-13
 m
2
 s
-1
 (Appendix 1 and Appendix 2).  
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MB release kinetics from the composite implant can be well described as a diffusion-
controlled process. Such description is suitable for the given experimental conditions because 
the diffusive transport of MB through the hydrogel-rich phase of the implant proceeds 
significantly slower compared to the rate of electrostatic interactions involved in MB release. 
Because of the monolithic structure of the reservoir, constant Da is an adequate parameter for 
the characterization and prediction of the release kinetics.  
Value of Da for the composite reservoir calculated from experimental data is about two orders 
of magnitude lower than the diffusion coefficient reported for MB in free poly(ethylene 
glycol) diacrylate hydrogels.
[29]
 The following arguments could address this discrepancy. Thin 
surface layer with reduced hydrogel content could act as an effective rate-limiting barrier for 
MB diffusion. Additionally, the effective pore size between the hydrogel chains for cross-
linked PAA hydrogel is probably much smaller than that of the referenced poly(ethylene 
glycol) diacrylate hydrogels having a high concentration of cross-links that impose steric 
restrictions. We estimated the average pore diameter of cross-linked PAA hydrogel to be 2.62 
nm (Appendix 3) which is quite close to MB molecular size reported as 0.591 nm × 1.382 
nm.
[30]
 Both the structure of the surface layer and effective pore size, which control the release 
kinetics, could be modified by changing the compositions of the starting solution and 
nonsolvent bath used for implant preparation.  
3.5. Implant biocompatibility in vitro 
Mouse fibroblast cell line L929 was used for cytotoxicity evaluation of the implants, as is 
routinely carried out in biomaterials research.
[31,32]
 Figure 5a shows that the metabolic 
activity of L929 cells assessed by MTT reduction assay decreased in samples incubated with 
implants after 1 h of cultivation, compared to the control samples without implants. 
Additionally, Crystal violet test indicated lower adhesion potential of cells cultivated with 
implants at all times, as seen in Figure 5b.  
(Figure 5) 
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L929 cell line is a continuous adherent cell line, and its ability to adhere influences cell 
morphology and capacity to proliferate and differentiate.
[32]
 Therefore, the observed lack of 
adhesion could be responsible for decreased MTT reduction capability of the cells with 
implants 2 h following incubation, compared to the control. Khorasani et al.
[33]
 showed that 
hydrophobic and a more negative surface charge of biomaterials impaired the L929 cell 
membrane adhesion capacity, which could affect cell membrane function, and lead to 
decreased metabolic activity. These observations are in line with our results as the implants 
were negatively charged (carboxyl groups). A study of endothelial cell incubation on different 
functionalized surfaces also confirmed that surface carboxyl groups led to the decrease in cell 
attachment and growth.
[34]
 
Primary cells were isolated from the spleen of the rat and cultured in the presence of implants 
for 24 and 48 h to investigate further the cytotoxic effects of implants. As shown by Trypan 
blue assay results in Figure 6a, the implants did not affect cell viability. However, Figure 6b 
shows that the MTT test results indicated a significantly higher metabolic activity in samples 
with implants following 48 h of incubation. MTT reduction following 48 h after incubation is 
in line with other studies showing the stimulatory potential of biomaterials on cell 
metabolic/mitochondrial functions.
[32,35]
 The apparent discrepancy in MTT reduction potential 
between L929 cell line and splenocytes could be explained by the difference in the functional 
aspects of these two cell types and their distinct origin and requirements. Apart from the fact 
that adhesion is a limiting step in L929 cells activity, these cells could be more sensitive to 
biomaterials compared to primary cells.
[31]
  
(Figure 6) 
Along with cytotoxicity, the potential of biomaterial to elicit an inflammatory reaction is also 
an important aspect in biocompatibility assessments. We observed lower levels of NO in 
supernatants of cells incubated with implants compared to the control, thus demonstrating no 
proinflammatory effect of the biomaterial on spleen cells. Moreover, as depicted in Figure 6c, 
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a diminished response to ConA stimulation implies the immunosuppressive potential of 
implants. NO is a well-known inflammatory mediator
[36]
 and its reduction by splenocytes 
cultivated with implants indicates the lack of direct proinflammatory potential of implants 
compared to the control. Additionally, splenocytes cultured with implants failed to respond to 
stimulation with common lymphocyte mitogen ConA, which highlights the suppressive effect 
of implants on basic proinflammatory pathways in vitro.  
3.6. Implant biocompatibility in vivo 
A rat model of subcutaneous implant installation was used to obtain initial information 
concerning the biocompatibility of these new materials through the pilot in vivo study. 
Regarding systemic effects, peripheral blood parameters – differential leukocyte counts and 
biochemical parameters (Table S1, Supporting Information), we observed a drop in total 
leukocyte numbers and percentage of neutrophils on days 1 and 3 p.i., a statistically 
significant increase in percentages of mononuclear cells, eosinophils, and basophils on day 1, 
and a decrease in platelet count, between sham-operated and implanted rats. On day 7 p.i., a 
statistically significant drop in the percentage of monocytes, as well as an increase in 
eosinophils were noted in implanted rats. Slight differences in the drop of leukocyte numbers 
on account of neutrophils on days 1 and 3 p.i. imply the recruitment of these early immune 
responders into the skin area around the implant. Increased percentage of monocytes, 
eosinophils, and basophils could represent a transient inflammatory response to the implant. 
Although elevated numbers of eosinophils could reflect an allergic property of implants, their 
presence, however, might be perceived as homeostatic/immunoregulatory.
[37]
 
Levels of proinflammatory cytokines TNF-α and IL-6 in the serum of all rats were below the 
level of method detection. Judged by the undetectable levels of these innate immune 
proinflammatory cytokines in the serum of implanted rats, the implanted material caused no 
systemic proinflammatory reaction. 
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Histological examination of skin overlying the implants and skin from sham-operated rats 
showed edematous, loose connective tissue in both animal groups on day 1 but with more 
compact clusters of cell debris and young connective tissue (pseudocapsule in formation) in 
the group of animals with implants as illustrated in Figure 7a,b. Time-dependent connective 
tissue formation/organization characteristic for pseudocapsule formation was seen in this 
group of animals, with more edematous connective tissue in the group with implants at day 7 
as compared to more compact cellular connective tissue (early phase of scar formation) in the 
skin of sham-implanted rats as shown in Figure 7c,d. No cell infiltration into implants was 
observed (Figure S2, Supporting Information).  
(Figure 7) 
Formation of fibrous capsule represents a normal host response to a foreign body, but the 
slower formation of scar tissue in the skin of implanted individuals is an indication of slower 
wound healing that might be ascribed to properties of the implant surface. Wet implant 
surface exhibits a high concentration of hydrophilic and negatively charged carboxyl groups 
that may reduce protein adsorption and partially inhibit cell growth, as reviewed in Tang et 
al..
[38]
 
Regarding local skin activity response to the foreign material, metabolic activity increased in 
skin explants from implanted animals at all times (except 0 h first day and 24 h seventh day 
p.i.), as illustrated in Figure 8a. The increase of MTT reduction by skin explants, in 
compliance with our in vitro studies on splenocytes, could reflect the increased proliferative 
activity of epithelial cells attempting to protect the vulnerable skin area. 
(Figure 8) 
As Figure 8b shows, NO production by skin explants from implanted rats increased on day 1 
p.i. and then returned to the basal level. This increased production of NO by skin explants 
could be responsible for impaired wound healing as NO is, apart from being an early 
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inflammatory marker, also known as a signaling molecule that prevents thrombosis by 
inhibiting platelets activation.
[39]
 Alternatively, it might be viewed as the host attempt to 
stimulate wound healing, given the important role of this mediator in the healing process.
[40]
 
As Figure 8c shows, there was no difference in TNF-α and IL-6 production by skin explants 
between control and implanted rats. Similar production of these cytokines by skin explants in 
implanted and sham-operated rats further suggests the absence of proinflammatory effect. 
General lack of the effect of implants on inflammatory cytokine production illustrates their 
low toxicity to the covering skin. 
4. Conclusions 
We presented a simple and robust synthesis method for the fabrication of implantable DL-
PLCL/PAA composite reservoirs for cationic drugs. The implants exhibited good ion-
exchange capacity, moderate swelling degree and the capability for fast reversible swelling 
within a few minutes while retaining the original geometry. In vitro drug loading and release 
experiments using MB as the model drug showed excellent loading efficiency and diffusion-
controlled release kinetics during two weeks.  
Biocompatibility of the unloaded reservoirs was examined through a series of in vitro tests 
and a pilot experiment in vivo. Implants exhibited low toxicity in vitro and in vivo, while the 
in vivo acute response analysis showed a normal foreign body reaction and early stages of 
slow fibrous capsule formation, which is beneficial for controlled drug delivery over longer 
periods. Interaction of the unloaded reservoir with the biological environment is mainly 
determined by the presence of free carboxyl groups on the surface that makes the surface 
highly hydrophilic and negatively charged. However, implantable reservoirs loaded with 
cationic drugs are expected to have different time-dependent surface properties, and their 
biocompatibility is one of the crucial topics for our future research.  
Obtained implantable composite drug reservoirs could serve as a versatile tool for controlled 
delivery of cationic drugs. Key implant properties relevant for drug delivery can be tuned 
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already in the synthesis stage through the modifications of the precursor solution composition 
and mold geometry. Some additional modifications of implant properties will be investigated 
in the future to suppress fibrous capsule formation and improve their performance over longer 
time periods. 
 
Supporting Information 
Supporting Information is available from the Wiley Online Library or from the author.  
 
Appendix 1. Model of drug diffusion from monolithic cylindrical reservoirs 
When the drug is dissolved within the monolithic carrier matrix, it exists in the form of a 
solution where drug molecules are nearly uniformly distributed in the reservoir material. The 
rate of drug release by diffusion from monolithic reservoirs is influenced by reservoir 
geometry.
[41]
 Release kinetics controlled by diffusion through the reservoir of cylindrical 
geometry can be described by
[42]
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where Mt and M∞ are the cumulative amounts of released drug at time t and infinity (or 
equilibrium), respectively; n and p are the dummy summation variables; qn are the roots of the 
Bessel function of the first kind and zero order (J0 (qn) = 0), R is the cylinder radius, H is the 
cylinder height, and Da is the apparent diffusion coefficient. The analytical expression in 
Equation (A1) converges quite slowly for small times and requires a large number of series 
terms to be numerically evaluated with acceptable accuracy. Very good approximation of the 
analytical expression for small times adequate for numerical evaluation is given by the 
expansion
[43]
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where L is half of the cylinder height H. For small values of L/R, the first four terms of the 
expansion already provide sufficient accuracy in most cases. If we assume that L/R = 0, the 
expression is reduced to the small time approximation for the plane sheet which can also be 
used as an approximation for very thin disks. 
Da can be evaluated from experimental data via nonlinear regression by applying the gradient 
descent optimization algorithm. Approximation for small times expressed as appropriately 
truncated expansion may be used as a regression model with good accuracy. 
Appendix 2. Calculation of Da of the composite reservoir 
Da was determined from nonlinear regression by applying the gradient descent optimization 
algorithm with two variable parameters: Da as the presumably constant apparent diffusion 
coefficient and b as the ordinate intercept. Through independent iterative variations of Da and 
b with fixed steps, the sum of squared errors was minimized. As the regression model, we 
used the expression 
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which was applied to the region of six initial experimental time points. The values of L = 
0.629 mm and R = 6.5 mm were determined from initial weights of the wet implants loaded 
with MB and measurements with a liner. The initial value of Da = 2.815 × 10
-13
 m
2
 s
-1
 was 
determined from the slope of linear fit shown in Figure 4 assuming thin disk approximation 
for the implant geometry. The initial value of b = 0 was chosen assuming no additional 
barriers to diffusion. Calculated values obtained by this algorithm were Da = 3.54 × 10
-13
 m
2
 s
-
1
 and b = -0.259 with the adjusted coefficient of determination R
2
 = 0.9971. Comparison of 
the experimental data and the fitted curve is illustrated in Figure A1. Code of the algorithm 
(MATLAB script: calculation of Da for cylindric composite reservoir geometry, 
Supporting Information) was written in the MATLAB programming package (MATLAB 
R2016b, The MathWorks, Inc., Natick, Massachusetts, United States). The implemented 
algorithm converged successfully (Figure S1, Supporting Information). 
(Figure A1) 
Appendix 3. Pore size estimation of the composite reservoir 
An estimate of the pore size of the composite reservoir was made via the gel correlation 
length model. Estimation of the correlation length was performed according to the PAA gel 
correlation length model explained in detail by Hu and Dickson (see
[44]
 and references 
therein). Mean mesh size between the interchain crossings ξ is designated as the correlation 
length with the assumption that ξ equals the effective reservoir pore diameter. ξ can be 
evaluated using the following expressions 
𝜉 ≅ (𝐿B +
1
16𝜋𝑙B𝐴C𝑐
)
−
1
4 (4𝜋𝐴C𝑐)
1
8(𝐴C𝑐)
−
3
4      (A4) 
𝑐 =
𝐴V𝜙
𝑣𝑀W
          (A5) 
where LB is the bare persistence length, lB is the Bjerrum length, AC is the contour distance of 
two adjacent charge groups along the polymer chain, c is the concentration of the charged 
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segments, AV is the Avogadro constant, ϕ is the PAA gel volume fraction, v is the partial 
specific volume of the PAA gel in the reservoir, and MW the molecular weight of the 
monomer. 
PAA gel volume fraction ϕ was calculated via the expression from the studies of Zhou and 
coworkers (see
[45]
 and references therein) 
𝜙 =
(𝑚d−𝑚0)𝑣
𝑉−𝑚0/𝜌DL−PLCL
         (A6) 
where md is the dry mass of the reservoir sample, m0 mass of the nascent DL-PLCL substrate, 
V the reservoir sample volume, and ρDL-PLCL the mass density of DL-PLCL.  
Pore diameter values were extrapolated from the graph in Figure 4 of the reference
[44]
 using 
linearization and extension of the log-log plot. For the unloaded reservoirs in the swollen state 
(equilibrated in PBS at pH = 7.4 and I = 0.154 M), the obtained effective mean pore diameter 
is 2.62 nm. The estimated mean pore diameter is reduced to 2.22 nm for the reservoirs loaded 
with MB.           
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Figure 1. FTIR-ATR spectra of (a) the pure polymer base (DL-PLCL) and dry implant (DL-
PLCL/PAA (dry)) and (b) dry (DL-PLCL/PAA (dry)) and wet (DL-PLCL/PAA (wet)) 
implant. 
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Figure 2. SEM images of the implant prepared from the casting solution composition with 16 
wt% DL-PLCL, 3.41 mmol g
-1
 AA, and 10 mol% TMPTA: implant surface ((a) and (b)) and 
implant cross section ((c) and (d)). 
 
 
Figure 3. Swelling of the composite implant: (a) shape of the dry implant (left) and wet 
implant equilibrated in PBS (right); (b) swelling kinetics and the fitted sigmoidal dependence 
using the Boltzmann function. Error bars correspond to the ± SD. 
 
 
Figure 4. The release of MB in PBS buffer at 37 °C presented as a relative cumulative amount 
of released MB (Qt/Qe) versus square root of time (t
0.5
) to illustrate the diffusion-controlled 
kinetics.  
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Figure 5. Metabolic activity and adhesion potential of L929 cells without (cells) and with 
(cells+implant) the implant: (a) MTT reduction and (b) Crystal violet test. Data are presented 
as the mean ± SD. Significance at: *P < 0.05 for cells vs cells+implant. 
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Figure 6. Viability, metabolic activity and NO production of spleen cells without (cells) and 
with (cells+implant) the implant: (a) Trypan blue exclusion, (b) MTT reduction, and (c) NO 
production. Data are presented as the mean ± SD. Significance at: *P < 0.05 and **P < 0.01 
for cells vs cells+implant and ^P < 0.05 for non-stimulated (-ConA) vs ConA stimulated NO 
production (+ConA). 
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Figure 7. Representative skin histology (sham-operated rats (SOR), implanted rats (IMR), 
image magnification 40x). Day 1: Loose connective tissue in SOR and more compact 
connective tissue with clusters of cell debris in IMR. Day 7: Compact layer of connective 
tissue in SOR and a more edematous layer of connective tissue in IMR. 
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Figure 8. Local effects of implants on (a) MTT reduction, (b) NO production, and (c) 
cytokine production. Data are presented as the mean ± SD. Significance at: *P < 0.05 sham vs 
implant. 
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Figure A1. Comparison of the measured MB release kinetics from disk-shaped composite 
implants (solid line) and MB release kinetics predicted by the model for monolithic cylinders 
(dotted line). The parameter values are Da = 3.54 × 10
-13
 m
2
/s and b = -0.2587. Error bars 
shown for experimental points correspond to ± 3SD. 
 
Table 1. Basic properties of prepared implants (MSD in PBS, WC, and Ccg) with their 
corresponding SDs 
Casting solution 
composition 
MSD 
[%] 
WC 
[%] 
Ccg 
[mmol g
-1
] 
16 wt% DL-PLCL 346 ± 6 77.6 ± 0.3 2.06 ± 0.01 
3.41 mmol g
-1
 AA    
10 mol% TMPTA    
 
Composite implantable reservoir for cationic drugs is fabricated by a robust method 
combining photoirradiation and liquid phase inversion. Synthesized reservoir exhibits fast 
reversible swelling, excellent loading efficiency, good ion exchange capacity and diffusion-
controlled release in vitro during two weeks. The unloaded reservoir has low acute toxicity 
and evokes a normal acute foreign body reaction in vivo.  
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MATLAB script: calculation of Da for cylindric composite reservoir geometry 
% Full model for monolithic cylinder diffusion with numerical approximation 
  
% apparent diffusion coefficient D [m^2/s] 
% measure of boundary layer resistance b 
% FR = Mt/Minf = Qt/Qe is the fractional release 
  
% Optimization with gradient descent method applied on b (flag = 1) and D (flag = 2) 
  
clear all 
clc 
close all 
  
% Implant geometry (cylinder dimensions measured by a caliper) 
R = 6.5e-3; % cylinder radius [m] 
H = 1.258e-3; % cylinder height [m] 
L = H/2; % half of cylinder height (used in the model) [m] 
  
% Measured values for the release kinetics of MB 
t = 24*3600*[2,4,7,9,11,14,17,21,24,28]; % time points of MB release [s] 
FR_m = [0.242,0.41,0.572,0.69,0.786,0.887,0.971,0.996,1,1]; % measured FR of MB 
FR_m_std = [0.003961881,0.011236789,0.017368022,0.02284146,0.020116839,... 
    0.018314712,0.007553963,0.001669337,3.24056e-05,0];% standard deviation 
% of 3 experiments with FR measurements for MB 
  
N = 6; % number of initial time points used for fitting 
t_f = t(1:N); % time vector for fitting 
FR_m_f = FR_m(1:N); % FR vector for fitting 
FR_m_std_f =FR_m_std(1:N); % FR standard deviation for fitted points 
FR_terms = zeros(N,4); % numerical approximation terms used in the model 
  
% Initial values of variable parameters and steps for change 
b = 0; % initial value of intercept corresponding to the boundary layer resistance 
bs = 1e-4; % iterative step for b 
step_sign_b = 1; % direction of change for b 
D = 2.815e-13; % initial value of the apparent diffusion coefficient [m^2/s] 
Ds = 1e-17; % iterative step for D 
step_sign_D = 1; % direction of change for D 
  
I = 0; % number of iterations 
Imax = 2.5e4; % maximum number of iterations 
FR_s = zeros(1,N); % simulated FR obtained by the model 
SSE = zeros(1,Imax); % sum of squared errors 
test = 1; % control parameter 
 
% Implementation of the gradient descent algorithm 
  
while test 
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    I = I + 1; 
     
    % Calculation of the simulated FR at all time points 
    for n = 1:N 
        FR_terms(n,1) = ((D*t_f(n)/(L^2))^0.5)*(2/sqrt(pi) + 4*L/(R*sqrt(pi))); 
        FR_terms(n,2) = -(D*t_f(n)/(L^2))*(8*L/(R*pi) + (L/R)^2); 
        FR_terms(n,3) = ((D*t_f(n)/(L^2))^1.5)*((2/sqrt(pi))*(L/R)^2 - 1/(6*sqrt(pi))*(L/R)^3); 
        FR_terms(n,4) = ((D*t_f(n)/(L^2))^2)*((1/(3*pi))*(L/R)^3 - (1/8)*(L/R)^4); 
        FR_s(n) = sum(FR_terms(n,:))+ b; 
    end 
     
    SSE(I) = sum((FR_s-FR_m_f).^2); 
     
    if I > 1 
        delta = SSE(I)-SSE(I-1); 
         
        if (delta > 0) && (flag == 1) 
            step_sign_b = -step_sign_b; 
        elseif (delta > 0) && (flag == 2) 
            step_sign_D = -step_sign_D; 
        end 
        if mod(I,2) == 0 
            D = D + step_sign_D*Ds; 
            flag = 2; 
        else 
            b = b + step_sign_b*bs; 
            flag = 1; 
        end 
    end 
     
    if (I >= Imax) 
        test = 0; 
    end 
     
end 
  
Text_D =['Apparent diffusion coefficient is D = ',num2str(D) ,' m^2/s']; 
disp(Text_D) 
  
Text_b =['Intercept corresponding to the boundary layer resistance is b = ',num2str(b)]; 
disp(Text_b) 
Convergence plot of the gradient descent algorithm in the MATLAB script 
 
Figure S1. Convergence plot of the gradient descent optimization algorithm used to 
determine the apparent diffusion coefficient Da by fitting experimental data. 
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Hematological parameters of rats 
Table S1. Hematological parameters of sham-operated rats and rats with the implant. 
 
  
Day 1 
   
Day 3 
 
Day 7 
  
  
Sham Implant 
 
Sham Implant 
 
Sham Implant 
Parameter
a)
 
         
Le  10
9 
L
-1
 
 
8.4 ± 2.7
b)
 6.7 ± 0.9 
 
11.8 ± 0.2 7.8 ± 0.6 
 
10.0 ± 0.6 10.9 ± 0.8 
Ne  % 
 
52.6 ± 34.6 40.0 ± 16.9 
 
52.5 ± 28.9 30.0 ± 0.1 
 
32.0 ± 5.7 31.1 ± 4.4 
Ly  % 
 
46.0 ± 34.0 57.5 ± 16.3 
 
44.5 ± 28.9 57.1 ± 21.1 
 
66.1 ± 5.6 66.6 ± 4.8 
Mo  % 
 
0.6 ± 0.3 0.9 ± 0.3*
c)
 
 
0.8 ± 0.1 0.9 ± 0.2 
 
0.7 ± 0.2 0.4 ± 0.1* 
Eo   % 
 
0.35 ± 0.20 0.7 ± 0.2* 
 
1.6 ± 0.1 1.6 ± 0.3 
 
0.4 ± 0.1 1.4 ± 0.3* 
Ba   % 
 
0.5 ± 0.3 0.7 ± 0.1* 
 
0.5 ± 0.1 0.4 ± 0.1 
 
0.7 ± 0.1 0.50 ± 0.01 
          
RBC* 10
12
 
 
7.2 ± 0.4 7.0 ± 0.7 
 
7.0 ± 0.1 6.7 ± 0.2 
 
6.6 ± 0.3 6.9 ± 0.4 
Hg g L
-1
 
 
131.0 ± 5.7 131.5 ± 13.4 
 
127.5 ± 2.1 123.5 ± 2.1 
 
124.5 ± 4.9 129.5 ± 3.5 
HCT I I
-1
 
 
0.40 ± 0.03 0.40 ± 0.05 
 
0.40 ± 0.01 0.40 ± 0.01 
 
0.40 ± 0.02 0.40 ± 0.01 
MCV fL 
 
57.0 ± 0.3 58.9 ± 2.8 
 
58.3 ± 1.1 62.8 ± 3.9 
 
64.5 ± 0.3 62.6 ± 3.5 
MCH  pg 
 
18.3 ± 0.3 18.8 ± 0.1 
 
18.2 ± 0.1 18.5 ± 0.3 
 
18.9 ± 0.1 18.7 ± 0.4 
          
MCHC  g L
-1
 
 
321.5 ± 6.4 321.0 ± 14.1 
 
321.0 ± 5.6 295.0 ± 14.1 
 
293.5 ± 0.7 299.0 ± 9.9 
PLT *10
9
 
 
789.0 ± 93.3 719.0 ± 90.5* 
 
631.5 ± 109.6 625.5 ± 139.3 
 
645.5 ± 82.7 716.0 ± 91.9 
MPV  fL 
 
8.20 ± 0.07 8.3 ± 0.2 
 
7.7 ± 0.2 7.9 ± 0.1 
 
9.8 ± 0.6 9.7 ± 0.1 
PDW  % 
 
40.9 ± 1.1 40.3 ± 4.3 
 
39.3 ± 2.0 38.6 ± 3.6 
 
43.1 ± 4.1 39.0 ± 0.6 
PCT  L L
-1
 
 
0.6 ± 0.1 0.6 ± 0.1 
 
0.5 ± 0.1 0.5 ± 0.1 
 
0.6 ± 0.1 0.7 ± 0.1 
MPC  g L
-1
 
 
195.0 ± 1.4 192.5 ± 4.9 
 
184.5 ± 4.9 184.0 ± 1.4 
 
165.5 ± 0.7 165.0 ± 1.4 
          
PCDW   g L
-1
 
 
48.4 ± 0.1 45.1 ± 4.0 
 
42.7 ± 0.6 45.3 ± 1.4 
 
49.1 ± 0.1 48.1 ± 0.9 
a)
Abbreviations: Le-Leukocytes, Ne-Neutrophils, Ly-Lymphocytes, Mo-Monocytes, Eo-Eosinophils, Ba-
Basophils, RBC-Red Blood Cells, Hg-Hemoglobin, HCT-Hematocrit, MCV-Mean Corpuscular Volume, MCH-
Mean Corpuscular Hemoglobin, MCHC-Mean Corpuscular Hemoglobin Concentration, PLT-Platelet Count, 
MPV-Mean Platelet Volume, PDW-Platelet Distribution Width, PCT-Plateletcrit, MPC-Mean Platelet 
Component, PCDW-Platelet Component Distribution Width.;
b)
Data are presented as the mean ± SD.;  
c)
Significance at *P < 0.05 sham vs implant. 
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Histology of the implant/tissue interface 
 
Figure S2. Implant/tissue interface at day 1 and day 7 (image magnification 63x). Cell 
infiltration is not observed. 
 
 
